Sativex is approved in over 24 countries for the treatment of MS spasticity. It is also approved in some countries for managing pain.
Sativex is not available in the United States. However, it is currently awaiting FDA approval as a treatment for cancer pain. GW Pharmaceuticals expects to receive FDA approval for Sativex by 2015.
Sativex has also shown promise in treating the following conditions:
Neuropathic pain – Small trials found Sativex could reduce pain in patients with neuropathic pain of various causes.
Bladder dysfunction – A small trial found Sativex could reduce bladder symptoms in MS patients.
Spinal cord injury – Small trials found Sativex could improve pain, spasticity, and sleep quality in spinal cord injury patients.
Berman, J. S., Symonds, C., and Birch, R. (2004). Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 112: 299-306.
Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ (2010). Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 16:1349-59. doi: 10.1177/1352458510378020
Maurer, M., Henn, V., Dittrich, A., and Hofmann, A. (1990). Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur.Arch.Psychiatry Clin.Neurosci. 240: 1-4.
Rog, D. J., Nurmikko, T. J., Friede, T., and Young, C. A. (2005). Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 65: 812-819.
Wade, D. T., Makela, P. M., House, H., Bateman, C. and others. (2006). Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult.Scler. 12: 639-645.
Wade, D. T., Robson, P., House, H., Makela, P. and others. (2003). A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin.Rehabil. 17: 21-29.